Skip to content
DataLookout
Menu

NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

StatusRecruiting
PhasePhase 3
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 12 versions: 12 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 484 → 560 locations
  2. Minor Trial sites expanded: 479 → 484 locations
  3. Notable Eligibility criteria expanded, about 39 words
    • Trial sites expanded: 440 → 479 locations
    • Secondary endpoints: details revised at 2 of 13 entries
  4. Minor Trial sites expanded: 413 → 440 locationsv9
  5. Minor Trial sites expanded: 373 → 413 locationsv8
  6. Minor Trial sites expanded: 346 → 373 locationsv7
  7. Minor Trial sites expanded: 251 → 346 locationsv6
  8. Minor Trial sites expanded: 229 → 251 locationsv5
  9. Minor Trial sites expanded: 153 → 229 locationsv4
  10. Minor Trial sites expanded: 17 → 153 locations
    • Secondary endpoints revised (13)
    • Study title expanded, about 2 words
    v3
  11. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Enrollment target: 1500 to 1410
    • Study sites: 0 to 17
    • Start date changed from estimate of Dec 5, 2025 to Jan 6, 2026
    • Secondary endpoints revised (13)
  12. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival
Timeframe: Approximately 39 months
Progression Free Survival (PFS) assessed by blinded independent central review (BICR)
Timeframe: Approximately 32 months

Secondary (13)

Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by BICR
Progression Free Survival as assessed by Investigator
Confirmed ORR using RECIST v1.1 as assessed by investigator
Duration of Response (DoR) as assessed by BICR
Duration of Response (DoR) as assessed by Investigator
Show 8 moreShow less
Number of Participants With Adverse Events (AEs)
Number of Participants With Clinical Laboratory Abnormalities
Pharmacokinetics (PK): Serum concentrations of PF-08634404
Incidence of Anti-Drug Antibody (ADA) against PF-08634404.
Mean scores and Change from baseline in the global health status/quality of life (QoL) and physical function scores on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
Time to definitive deterioration (TTdD) in in the global health status/QoL and physical function scores on the EORTC QLQ-C30
Mean scores and Change from Baseline in dyspnea, cough, and chest pain scores on the EORTC Quality of Life Cancer Questionnaire - Lung Cancer 13 QLQ-LC13
TTdD in the dyspnea, cough, and chest pain scores on the EORTC QLQ-LC13

Arms and interventions

Arm AExperimental

Participants will receive PF-08634404 combined with chemotherapy regimen 1, followed by maintenance therapy with PF-08634404.

Arm BActive comparator

Participants will receive pembrolizumab combined with chemotherapy regimen 1, followed by maintenance therapy with pembrolizumab.

Arm CExperimental

Participants will receive PF-08634404 combined with chemotherapy regimen 2, followed by maintenance therapy with PF-08634404 and chemotherapy.

Arm DActive comparator

Participants will receive pembrolizumab combined with chemotherapy regimen 2, followed by maintenance therapy with pembrolizumab and chemotherapy.

Biologicals: PF-08634404, Pembrolizumab

Drugs: Chemotherapy Regimen 1, Chemotherapy Regimen 2

Sites

560 sites in 21 countries

United States 278, China 44, Japan 31, Spain 22, Brazil 20, Germany 15, India 15, Turkey (Türkiye) 15, Italy 14, Argentina 13, Australia 11, Taiwan 11, Canada 10, Greece 9, Poland 9, South Korea 9, France 8, Hungary 8, Czechia 7, Israel 6, Puerto Rico 5